FDA Proposes Reclassifying Oncology Nucleic Acid–Based Tests from Class III to Class II
The proposed order would shift these test systems to Class II with special controls, replacing the current PMA requirement for companion diagnostics and related oncology assays.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
